ACIU - AC Immune Ltd logo

AC Immune Ltd

ACIU

AC Immune develops therapies and diagnostics for neurodegenerative diseases, focusing on Alzheimer’s and Parkinson’s. Its platforms produce biologics and small molecules targeting misfolded proteins, aiming to slow disease progression and enhance diagnosis.

⚕️ Healthcare NASDAQ Listed 2016 CHF
$1,000 invested 10 years ago →$154today

Score Overview

1 Year
Score
Net Growth38.74%
Net TrendGrew
Net Income Consistency—
Rev Growth390.04%
Rev TrendGrew
Revenue Consistency—
5 Years
Score6.9
Net Growth40.88%
Net Trend80%
Net Income Consistency—
Rev Growth18x
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth-4x
Net Trend50%
Net Income Consistency
Rev Growth-24.58%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend50%
Net Income Consistency
Rev Growth-24.58%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where AC Immune Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ACIU does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 2.42—
1 Year2025-10-23
$ 2.81-13.88%
5 Years2021-10-22
$ 6.03-59.87%
10 Years2016-10-21
$ 15.68-84.57%
All Time2016-09-23
$ 15.66-84.55%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in CHF

Year
TTMCHF 17M-CHF 43M
2025CHF 3M-CHF 70MCHF 91M
2024CHF 27M-CHF 50MCHF 165M
2023CHF 14M-CHF 54MCHF 103M
2022CHF 3M-CHF 70MCHF 122M
2021CHF 944K-CHF 72MCHF 198M
2020CHF 15M-CHF 61MCHF 225M
2019CHF 110MCHF 45MCHF 288M
2018CHF 7M-CHF 50MCHF 186M
2017CHF 20M-CHF 26MCHF 124M
IPO2016CHF 23M-CHF 7MCHF 152M
ACIU - AC Immune Ltd logo

AC Immune Ltd fundamental performance

Between 2020 and 2025, revenue declined from CHF 15M to CHF 3M and net income went from -CHF 61M to -CHF 70M. Revenue increased in 4 of those 5 years; net income in 4.

Across AC Immune Ltd's full reported history, from 2016 to 2025, revenue declined from CHF 23M to CHF 3M and net income went from -CHF 7M to -CHF 70M. Revenue increased in 50% of the years measured; net income in 50%.

AC Immune Ltd currently holds a 5-year HDB Score of 6.9 out of 10. How the HDB Score is calculated.

Membership

Explore ACIU with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies